Evidence from various sources (Ziff, 1973) indicates that immune mechanisms are involved in the pathogenesis of intra-articular inflammation in patients with rheumatoid arthritis (RA). Since the effector limbs of immune inflammation can be partitioned into humoral and/or cell-mediated mechanisms (Craddock, Longmire, and McMillan, 1971) , it has been convenient for investigators to evaluate the relative contributions of each of these events to rheumatoid synovial inflammation. As a result, certain observations have been made which clearly document the participation of humoral immune inflammation in RA, including the demonstration of intrasynovial synthesis of immunoglobulin (Ig) and rheumatoid factor (Smiley, Sachs, and Ziff, 1968; Sliwinski and Zvaifler, 1970) , the presence of immune complex-like inclusions in intra-articular phagocytic cells (Hollander and others, 1965; Kinsella, Baum, and Ziff, 1969) , and the intra-articular activation and consumption of components of the complement (C) system (Ruddy, Gigli, and Austen, 1972) .
Only recently has the participation ofcell-mediated events in the pathogenesis of rheumatoid synovitis been definitively documented, showing that such participation may occur when RA synovial fluids (Stastny and others, 1973) and RA synovial extracts (Stanfield and others, 1967; Bacon and others, 1973) are used as in vitro stimulants.
Previous work by the author has shown that the majority of RA synovial fluids can induce in vitro blastogenic transformation of autologous peripheral blood lymphocytes from subjects with RA (Kinsella, 1973) . The present study extends this observation and also evaluates the induction of in vitro blastogenesis by allogeneic synovial fluids as well as examines various in vivo and in vitro correlates of the reaction.
Materials and methods

STUDY GROUPS
Donors of peripheral blood leucocytes, synovial fluid, or both, are given in Table I . All patients with RA had (Bennett and Burch, 1967) . All other patients had definitive diagnoses derived from the clinical as well as from appropriate biochemical, serological, radiological, and histological examinations. Thirty-two patients donated both lymphocytes and synovial fluid, nine donated lymphocytes alone, and six synovial fluid alone. At the time of these studies all RA patients were receiving acetylsalicylic acid therapy 1200-4800 mg/day; six were receiving 5-10 mg prednisone per day; two were receiving 250 mg antimalarials per day; and two received therapeutic doses of gold salts. In the groups without RA (non-RA) the majority were receiving 1200-3600 mg acetylsalicylic per day during acute exacerbations of synovitis, and eight were receiving a maximum of 400 mg phenylbutazone per day; six patients in this group were receiving no anti-inflammatory medication.
SEROLOGICAL STUDIES
Sera and/or synovial fluids of all patients were examined for the presence of rheumatoid factor (RF) by a slide latex test (Gibco-Grand Island Biologicals) and a micromethod modification ofa sensitized sheep cell test, employing reagents donated by the World Health Organization (Anderson and others, 1970) . Thirteen patients with RA were positive for RF and six were negative. Of the non-RA group only one synovial fluid donor with osteoarthrosis was positive for RF. Direct immunofluorescent staining was performed on washed cells recovered from aliquots of 30 of 38 synovial fluids (RA RF(+)11, RA-RF(-)5, rheumatic fever 3, ankylosing spondylitis 3, pseudogout 3, osteoarthrosis 2, miscellaneous 3), as described previously (Kinsella and others, 1969 Aspiration of SF was performed under sterile conditions. Aliquots of specimens were used for cytological, serological, and biochemical studies and the remainder collected in sterile polypropylene centrifuge tubes. In early studies centrifugation of SF was carried out at 26 860 x g at 40 C for 60 minutes in a JS-13 swinging bucket rotor in a Beckman J-21 centrifuge; subsequently it was found that centrifugation at 5720 x g was adequate and did not influence the blastogenicity of SF. After centrifugation, the upper one-half of each specimen was removed under sterile conditions and aliquots were diluted in volumes of heat inactivated (560C x 30 min) gamma globulin-free newborn calf serum (GG-Free Newborn Calf Serum, Gibco) sufficient to provide final dilutions of SF of 1/10, 1/20, and 1/40. Specimens were stored at -20°C until used in leucocyte cultures.
LEUCOCYTE CULTURES 50 ml of venous blood, containing 10,pm/ml heparin (Connaught Laboratories), were obtained from each cell donor. Red blood cells were usually sedimented by gravity at room temperature in an inverted syringe but in some instances several centrifugations at 75 x g were necessary to obtain adequate sedimentation of the red blood cells. The supernatant plasma thus obtained was centrifuged in glass tubes at 250 x g for 10 minutes and the resultant cell button washed three times in RPMI-1640 medium (Gibco) before resuspension in an amount of RPMI sufficient to obtain 5 x 105 small lymphocytes in 0-2 ml.
Leucocytes were cultured in polypropylene tubes (Falcon Plastics) in triplicate or quadruplicate in final volumes of 1-0 ml, containing 0-2 ml cell suspension, RPMI-1640 medium, 1% 200 mmol/l L-glutamine (Gibco), antibiotics, and 20 % ofeither heat inactivated calf serum alone (control cultures) or SF diluted in calf serum (experimental cultures); final dilutions of SF in each culture were 1/50, 1/100, and 1/200. In the majority of experiments parallel cultures of both RA SF and non-RA SF were included with lymphocytes from a single donor. Additional cultures containing phytohaemagglutinin (PHA-P, Difco) were established for all RA patients and for all but two non-RA patients; in these experiments PHA was added on day 0 for 3-day cultures and on day 3 for 51-day cultures (subsequently referred to as 5-day cultures).
Heat inactivated gamma globulin-free newborn calf serum (AGF), which was devoid of bovine C3 by Ouchterlony analysis (Ouchterlony, 1962) , was used as carrier and diluent serum since preliminary comparisons with a variety of serum supplements showed that AGF was less likely to induce 'spontaneous' blastogenesis of unstimulated cultures. Cultures were routinely maintained for b 0 NON-R A with autologous SF was 2a1 ± 05, range 06-8-3; only one subject, with pseudogout, had an SI > 3-0. The difference between the means of the two groups was significant (P < 002). In these experiments the mean SI was 03, range 0-8-4X0; SF from one patient each N pseudogout and OA gave an SI of 4 and 3, resp ively.
In Fig. 3b are shown the SI produced by r RA SF in 14 experiments with 9 allogeneic nonlymphocyte donors. The mean SI in these experim4 was 1 *6 + 0-6, range 0 5-4 0; SF from one patientv pseudogout, who was not the same patient note4 Fig. 3a, gave 
EFFECT OF DURATION OF CULTURE ON SF-INDUCED BLASTOGENESIS
The blastogenic effect of 6 RA SF and 6 non-RA SF in parallel cultures harvested after 3 days and 5 days significant blastogenesis at any dilution. When 18 allogeneic RA SF were cultured with non-RA lymphocytes 2 induced significant blastogenesis at one dilution and 6 at three dilutions, whereas 10 failed to induce blastogenesis at any dilution tested.
In cultures of allogeneic non-RA SF, 13 fluids were tested against RA lymphocytes and 2 were 'positive' at one dilution, while all others failed to induce significant blastogenesis at any dilution. Similarly, when 14 allogeneic non-RA SF were cultured with non-RA lymphocytes one fluid induced significant blastogenesis at two dilutions, whereas 13 were 'negative' at all dilutions employed.
In three experiments with autologous cultures (2 RA, 1 non-RA) and in five with allogeneic cultures (3 RA SF, 2 non-RA SF) using extended dilutions ranging from undiluted to 1/5000, no appreciable change in the frequency of significant blastogenesis was encountered (data not shown).
INFLUENCE OF THERAPY ON BLASTOGENIC RESPONSE
No inhibitory effect of drug therapy was evident from these studies. In particular, for patients with RA no correlation was found between type of therapy and quantitative blastogenic responses, including those on prednisone therapy of whom three displayed 'positive' and three 'negative' stimulation index.
INFLUENCE OF IN VIVO CORRELATES ON SF BLASTOGENESIS
Total and differential white blood cell counts did not correlate with either the frequency or degree of SF-induced blastogenesis. Similarly, the presence of RF in 13 of 32 SF did not correlate with the induction of blastogenesis (x2 = 2 9965; df 1; P > 0-1). However, significant correlations were found between the presence of intracellular Ig and C inclusions and SF-induced blastogenesis. Of 30 SF examined, intracellular Ig inclusions were present in 11 and absent in three with significant blastogenesis (SI >3), whereas such inclusions were present in 5 and absent in 11 without significant blastogenesis (x2 = 4-8469; df 1; P> 0-05). Similarly, immunofluorescent C3 inclusions were present in 11 and absent in 3 SF with significant blastogenesis, but were present in 4 and absent in 12 without significant blastogenesis (Q2= 6-5624; df 1; P > 0 025). Discussion These studies extend a previous report from this laboratory that, in contrast to non-RA SF, the majority of RA SF can induce in vitro transformation of autologous peripheral blood lymphocytes (Kinsella, 1973) . In addition, the results show that RA SF exert a quantitatively similar effect on allogeneic RA and non-RA lymphocytes. Thus, these studies indicate that RA SF can modulate a cell-mediated immune response in vitro, a conclusion supported by recent reports by other authors who used different techniques for assessing cellular immunity in vitro (Stastny and others, 1973; Bacon and others, 1973) . Since lymphocyte transformation in vitro is a reliable correlate of cell-mediated immunity in vivo (Bloom, Landy, and Lawrence, 1973) , it can be inferred that the in vitro studies reported here may reflect similar events in vivo and partially explain the persistent lymphoid proliferation observed in rheumatoid synovial membranes.
The identity of the blastogenic substance, or substances, in RA SF has not been specifically delineated. However, the demonstration of a positive correlation between SF-induced blastogenesis and the presence in SF of immunofluorescent intracellular Ig and C inclusions, which are considered to represent phagocytosed immune complexes (Bonomo and others 1970; Ziff, 1973) , suggests that the latter may Uhr, 1968) .
In addition, there are at least two other potential mitogens present in RA SF, namely, specific 'RA antigen' and aggregated gamma globulin. Although the former may contribute to the observed reaction, the absence of immunological specificity for RA lymphocytes indicates that SF-induced blastogenicity is not mediated exclusively by immune memory for such an antigen. On the other hand, the presence in some RA SF of aggregated gamma globulin (Hannestad, 1967) , which can induce in vitro lymphocyte transformation (Reynolds and Abdou, 1973; Kinsella, 1974) and inhibition of leucocyte migration (Brostoff, Howell, and Roitt, 1973) , suggests that the blastogenicity of RA SF may partially reflect the presence therein of aggregated gamma globulin.
The foregoing considerations and the results of the present studies suggest that the intra-articular milieu in patients with RA may be such that intrasynovial lymphocyte blastogenesis could occur under the influence of 'nonspecific', as well as specific, mitogens present in RA SF. Thus, in addition to their potential pathogenetic significance, these studies suggest that eradication or inhibition of intrasynovial lymphocyte blastogenesis is a rational therapeutic objective in the patient with rheumatoid arthritis.
